Related Experiment Video
Updated: Apr 21, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update
O De Backer1, S Arnous1, N Ihlemann1
1Department of Cardiology , Rigshospitalet , Copenhagen Ø , Denmark.
Insights
Atrial fibrillation (AF) stroke risk can be managed with left atrial appendage (LAA) occlusion. This minimally invasive procedure offers an alternative for patients unsuitable for oral anticoagulation therapy.
Area of Science:
- Cardiology
- Interventional Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) is a common arrhythmia linked to a high risk of stroke.
- Oral anticoagulation (OAC) is standard for stroke prevention but has limitations like bleeding and drug interactions.
- Newer oral anticoagulants also present risks, necessitating alternative stroke prevention strategies.
Purpose of the Study:
- To review the rationale behind left atrial appendage (LAA) closure for stroke prevention in AF patients.
- To discuss current LAA occlusion devices and their clinical evidence.
- To highlight the importance of patient selection, imaging, and post-procedural antithrombotic therapy.
Main Methods:
- Review of existing literature on LAA occlusion devices and clinical trials.
- Analysis of patient selection criteria for LAA closure.
- Discussion of imaging modalities and antithrombotic strategies post-procedure.
Main Results:
- Percutaneous LAA occlusion is a viable alternative for high-risk AF patients unsuitable for OAC.
- Several LAA occlusion devices are available, with accumulating clinical evidence supporting their efficacy.
- Optimal outcomes depend on careful patient selection, precise imaging guidance, and tailored antithrombotic regimens.
Conclusions:
- LAA occlusion represents a significant advancement in stroke risk management for specific AF populations.
- Further research and standardization of techniques are crucial for optimizing LAA closure therapy.
- Personalized approaches to patient selection and post-procedural management are key to maximizing benefits.
Abstract:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice. One of its most devastating complications is the development of thromboembolism leading to fatal or disabling stroke. Oral anticoagulation (OAC, warfarin) is the standard treatment for stroke prevention in patients with AF with an increased stroke risk. However, there are several obstacles to long-term OAC therapy, including the risk of serious bleeding, several drug-drug interactions and the need for frequent blood testing. Although newer oral anticoagulants have been developed, these drugs also face issues of major bleeding and non-compliance. Therefore, alternative treatment options for stroke prevention in patients with AF with a high stroke risk are needed. Percutaneous left atrial appendage (LAA) occlusion is an evolving therapy, which should be taken into consideration in those patients with non-valvular AF with a high stroke risk and contraindications for OAC. This article aims to discuss the rationale for LAA closure, the available LAA occlusion devices and their clinical evidence until now. Moreover, we discuss the importance of proper patient selection, the role of various imaging techniques and the need for a more tailored postprocedural antithrombotic therapy.
